NCT00291798View on ClinicalTrials.gov

Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane

PHASE2CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

September 30, 2000

Study Completion Date

March 31, 2009

Conditions
Breast Cancer
Interventions
PROCEDURE

rate of remission

Trial Locations (11)

1090

Medical University of Vienna, General Hospital, Vienna

1140

Hanusch Hospital, Vienna

2700

Hospital of Wiener Neustadt, Wiener Neustadt

4010

Hospital BHS Linz, Linz

4020

General Hospital Linz, Linz

5020

Paracelsus Medical University Salzburg, Oncology, Salzburg

7540

Hospital of Guessing, Güssing

8036

Gynaegological Medical University of Graz, Graz

Medical University of Graz, Oncology, Graz

9026

State Hospital Klagenfurt, Surgery, Klagenfurt

9400

State Hospital Wolfsberg, Wolfsberg

All Listed Sponsors
collaborator

Pharmacia Austria GmbH

UNKNOWN

lead

Austrian Breast & Colorectal Cancer Study Group

NETWORK

NCT00291798 - Neoadjuvant Endocrinotherapy of Breast Cancer (Mamma Carcinoma) With Exemestane | Biotech Hunter | Biotech Hunter